Will CROs Take On the Risks of Strategic Outsourcing?

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-06-02-2004, Volume 28, Issue 6

It's not clear whether contract service providers can deliver the performance improvements and costs savings that drug companies expect from large, long-term, semi-exclusive contracts.

Related Content:

Bio/Pharma BusinessOutsourcingOutsourcing OutlookContract Manufacturing, GeneralPharmaceutical Technology-06-02-2004
Alentis Therapeutics to Advance Anti-Claudin-1 ADCs to Treat Solid Tumors on $181.4 Million Financing
Avantor Sees Future of Opportunities with Growing Development of Next-Gen Biotherapeutics
Merck and Ginkgo Bioworks’ Collaboration to Improve Biologics Manufacturing Has Reached Its First Milestone